Health Communications for Adults Smoking Nondaily

August 26, 2026 updated by: Bethany Shorey Fennell, PhD
The goal of this study is to develop smoking health risk messaging targeted to adults who smoke some days, but not smoke every day (nondaily). The main purpose is to learn what type of smoking health risk messages will be most likely to encourage adults nondaily to quit completely. Aim 1will iteratively obtain qualitative feedback from adults smoking nondaily on initial message designs, resulting in 12 final messages. Aim 2 will test message properties using a 2 (health vs. social messages) x 2 (positive vs. negative messages) between subjects design to ascertain which messages promote proximal outcomes associated with quitting cigarettes (e.g., new knowledge, risk perceptions, motivation and intentions to quit).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
320

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Kentucky
      • Lexington, Kentucky, United States, 40506
        • University of Kentucky

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • individuals that report smoking at least one combustible cigarette per day on 4-28 days in the past 30 days
  • able to read/write in English
  • able to give informed consent
  • no history of daily smoking

Exclusion Criteria:

  • enrolled in smoking cessation treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Positive Health Messaging (PH)
Behavioral: Targeted Smoking Messages
Participants will view 3 messages within the assigned condition (PH, PS, NH, NS) in a random order. Each message will be displayed for a minimum of 30 seconds.
Active Comparator: Negative Health Messaging (NH)
Behavioral: Targeted Smoking Messages
Participants will view 3 messages within the assigned condition (PH, PS, NH, NS) in a random order. Each message will be displayed for a minimum of 30 seconds.
Experimental: Positive Social Messaging (PS)
Behavioral: Targeted Smoking Messages
Participants will view 3 messages within the assigned condition (PH, PS, NH, NS) in a random order. Each message will be displayed for a minimum of 30 seconds.
Experimental: Negative Social Messaging (NS)
Behavioral: Targeted Smoking Messages
Participants will view 3 messages within the assigned condition (PH, PS, NH, NS) in a random order. Each message will be displayed for a minimum of 30 seconds.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Knowledge
Time Frame: Baseline and post-intervention (approximately 1 hour)
Knowledge will be assessed with items based on the ITC-4 (International Tobacco Control (ITC) Four Country Survey) that map onto information presented in the messages (e.g., "Does smoking cause…" heart disease, lung cancer in others; Yes, No, I don't know)
Baseline and post-intervention (approximately 1 hour)
Change in Worry
Time Frame: Baseline and post-intervention (approximately 1 hour)
Worry will be assessed with 4 items, "How [worried, anxious, fearful, concerned] are you about the effects of smoking?" (1=Not at all, 7=Extremely).
Baseline and post-intervention (approximately 1 hour)
Change in Risk perception
Time Frame: Baseline and post-intervention (approximately 1 hour)
Risk perceptions will be assessed with 3 items, "If you [don't/do] quit smoking for good, what are your chances of ever developing a smoking-related health problem?" and "How susceptible do you feel you are to developing a smoking-related health problem?" (1=Lowest susceptibility, 7=Highest susceptibility). These will be averaged to form a measure of personal absolute risk
Baseline and post-intervention (approximately 1 hour)
Change in the Contemplation Ladder
Time Frame: Baseline and post-intervention (approximately 1 hour)
Motivation to quit will be measured with the Contemplation Ladder, rating the position on an 11-rung ladder (0-10) corresponding to stages from "no thought of quitting" (0) to "taking action" (10)
Baseline and post-intervention (approximately 1 hour)
Change in the Motivation to Stop Scale
Time Frame: Baseline and post-intervention (approximately 1 hour)
Motivation to quit will be measured with the Motivation to Stop Scale, Level of motivation to stop smoking is measured with seven response categories ranging from 1 (lowest) to level 7 (highest level of motivation to stop smoking)
Baseline and post-intervention (approximately 1 hour)
Change in intention to quit
Time Frame: Baseline and post-intervention (approximately 1 hour)
Intention to quit will be measured with the question "What best describes your intent to stop smoking completely, not even a puff?" (1=Never expect to quit, 4=Will quit in the next 30 days)
Baseline and post-intervention (approximately 1 hour)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bethany Shorey Fennell, PhD

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Cancer Institute (NCI)

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Bethany Shorey Fennell, PhD, University of Kentucky

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 17, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 18, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 18, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 22, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 26, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 94633
  • R03CA286623 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings